Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in: Drugs & Therapy Perspectives 8/2012

01-08-2012 | Disease Management

Pharmacological options for maintenance treatment of opioid dependence include opioid agonists and antagonists

Published in: Drugs & Therapy Perspectives | Issue 8/2012

Login to get access

Excerpt

Opioid dependence is a chronic, relapsing condition that manifests as addiction to heroin and pharmaceutical opioids.[1] A worldwide increase in the misuse of opioids has been observed.[2] Globally, there are an estimated 15.6million illicit opioid users, 11 million of whom primarily use heroin. …
Literature
1.
Tetrault JM, Fiellin DA. Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs 2012; 72 (2): 217–28PubMedCrossRef
2.
World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO Press, 2009
3.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: fourth edition. DSM-IV. Washington, DC: American Psychiatric Association, 1994
4.
Hallinan R, Byrne A, Agho K, et al. Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. Int J Androl 2009; 32 (2): 131–9PubMedCrossRef
5.
Kim TW, Alford DP, Malabanan A, et al. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend 2006; 85 (3): 258–62PubMedCrossRef
6.
Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150 (6): 387–95PubMedCrossRef
7.
8.
Anchersen K, Clausen T, Gossop M, et al. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 2009; 104 (6): 993–9PubMedCrossRef
9.
Dolophine® hydrochloride (methadone hydrochloride tablets, USP) 5 mg, 10 mg: US prescribing information. Columbus (OH): Roxane Laboratories, Inc., 2006 Oct
10.
Reynaud M, Petit G, Potard D, et al. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998; 93 (9): 1385–92PubMedCrossRef
11.
Deamer RL, Wilson DR, Clark DS, et al. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J Addict Dis 2001; 20 (4): 7–14PubMedCrossRef
12.
Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Syst Rev 2011; (4): CD001333
13.
Tetrault JM, Tate JP, McGinnis KA, et al. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res 2012 Feb; 36 (2): 318–24PubMedCrossRef
14.
Vivitrol® (naltrexone for extended-release injectable suspension) 380 mg/vial: US prescribinginformation. Waltham(MA): Alkermes, Inc., 2010 Oct
15.
Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA 2010; 304 (14): 1576–83PubMedCrossRef
16.
Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev 2010; (8): CD003410
17.
Ward J, Rosenbaum C, Hernon C, et al. Herbal medicines for the management of opioid addiction: safe and effective alternatives to conventional pharmacotherapy? CNS Drugs 2011; 25 (12): 999–1007PubMedCrossRef
Metadata
Title
Pharmacological options for maintenance treatment of opioid dependence include opioid agonists and antagonists
Publication date
01-08-2012
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 8/2012
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.1007/BF03262113

Other articles of this Issue 8/2012

Drugs & Therapy Perspectives 8/2012 Go to the issue

Adis Drug Clinical Q&A

Fixed-dose naproxen/esomeprazole magnesium: a guide to its use to treat arthritic symptoms and reduce gastric ulcer risk

Drug Reactions and Interactions

First reports of serious adverse drug reactions in recent weeks

Pharmaceutical Care: Original Research Article

Why people refuse generic substitution: a population survey of public opinion on generic substitution in Finland

Adis Drug Clinical Q&A

Ustekinumab: a guide to its use in plaque psoriasis

Practical Issues and Updates

Vitamin products, in particular multi-vitamins, may potentially enhance cognitive function, but more studies are needed

Disease Management

Treat cutaneous warts on a case-by-case basis, taking into account patient factors and the available clinical evidence